Downregulation of IFNAR is found during tumor development in melanoma patients and expression of a non-degradable IFNAR1 mutant in mice was shown to delay the formation and progression of melanoma and increase responsiveness to BRAF or PD-1 inhibitors in vivo [196]. Here, IFNAR1 is linked to neoplasm.